drugset
Drugs / Cannabidiol
last change 3 days ago re-read 2 minutes ago

Cannabidiol

also known as CBD · Epidiolex · GWP42003-P · GWP42003 · Medical Cannabis · Epidyolex · bsCBD · CardiolRx · +32 more

Other / unclassified targets CES1, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4, NLRP3, UGT2B7 via inhibition

Developed for
epilepsy · Dravet syndrome · Lennox-Gastaut syndrome · schizophrenia · anxiety · cannabis dependence · chemotherapy-induced neuropathy · alcohol-related disorders
+127 more · opiate dependence · osteoarthritis, knee · post-traumatic stress disorder · multiple sclerosis · social phobia · tuberous sclerosis · alcohol dependence · autism spectrum disorder · bipolar disorder · COVID-19 · diabetic polyneuropathy · fragile X syndrome · infantile spasms · malignant pancreatic neoplasm · substance-related disorder · acute graft versus host disease · breast cancer · cancer · chronic pain syndrome · colon carcinoma · colorectal cancer · depressive disorder · generalized anxiety disorder · glioblastoma · insomnia · neuropathy, painful · sleep disorder · acne · Alzheimer disease · arthropathy · autism · breast carcinoma · childhood absence epilepsy · dysmenorrhea · endometriosis · female breast carcinoma · fibromyalgia · graft versus host disease · HIV infectious disease · musculoskeletal system disorder · nicotine dependence · Parkinson disease · Prader-Willi syndrome · psychotic disorder · Rett syndrome · schizoaffective disorder · Sturge-Weber syndrome · temporomandibular joint disorder · Tourette syndrome · ulcerative colitis · acute myocarditis · agoraphobia · alcohol abuse · alcohol withdrawal · amyotrophic lateral sclerosis · anorexia nervosa · attention deficit-hyperactivity disorder · autoimmune hepatitis · bipolar depression · bruxism · burn goodship syndrome · carpal tunnel syndrome · castration-resistant prostate carcinoma · chronic periodontitis · chronic urticaria · cognitive impairment with or without cerebellar ataxia · Crohn disease · dementia · dental abscess · dentin sensitivity · diabetic neuropathy · disruptive behavior disorder · epidermolysis bullosa · epilepsy with myoclonic atonic seizures · essential tremor · fatty liver disease · focal epilepsy · headache disorder · heart failure · hepatocellular carcinoma · Huntington disease · hyperlipidemia · hypoproteinemia, hypercatabolic · inherited epidermolysis bullosa · intellectual disability · interstitial cystitis · major depressive disorder · migraine disorder · mood disorder · mucopolysaccharidosis type 3 · myofascial pain syndrome · obsessive-compulsive disorder · osteoarthritis · osteoarthritis, hand · panic disorder · pericarditis · periodontitis, chronic, adult · plasma cell myeloma · post-traumatic epilepsy · prostate adenocarcinoma · psoriatic arthritis · radiculopathy · rectal cancer · rheumatoid arthritis · rifampicin-resistant tuberculosis · rotator cuff syndrome · substance withdrawal syndrome · systemic sclerosis · temporomandibular joint dysfunction syndrome · tooth hard tissue disease · treatment-refractory schizophrenia · trichotillomania · unexplained long-lasting fever/inflammatory syndrome · urolithiasis · vascular dementia · allesthesia · atopic eczema · benign essential blepharospasm · cocaine dependence · developmental and/or epileptic encephalopathy with spike-wave activation in sleep · dyspepsia · early-onset schizophrenia · gastroparesis · sickle cell disease · substance dependence · traumatic brain injury · type 2 diabetes mellitus
Investigated by
Jazz Pharmaceuticals · National Institute on Drug Abuse (NIDA) · Johns Hopkins University · Central Institute of Mental Health, Mannheim · University of California, San Diego · INSYS Therapeutics Inc
+308 more · NYU Langone Health · Tilray · Yale University · Center for Medicinal Cannabis Research · GW Research Ltd · National Center for Complementary and Integrative Health (NCCIH) · Radius Pharmaceuticals, Inc. · University of California, Los Angeles · University of Colorado, Denver · University of Florida · King's College London · Mclean Hospital · Medical University of South Carolina · National Cancer Institute (NCI) · Rabin Medical Center · University of Cologne · University of Colorado, Boulder · University of Sao Paulo · Assistance Publique - Hôpitaux de Paris · Canadian Institutes of Health Research (CIHR) · Cardiol Therapeutics Inc. · City of Hope Medical Center · Consortium for Medical Marijuana Clinical Outcomes Research · GW Pharmaceuticals Ltd · Hadassah Medical Organization · Hurd,Yasmin, Ph.D. · Icahn School of Medicine at Mount Sinai · Jazz Pharmaceuticals Research UK Limited · Ludwig-Maximilians - University of Munich · McMaster University · Pure Green · Stero Biotechs Ltd. · University of Copenhagen · University of Minnesota · University of Montreal Hospital Centre (CHUM) · University of Nebraska · University of Sydney · Wayne State University · Aalborg University Hospital · Amsterdam University Medical Center · Ananda Scientific · Anne Comi, MD · Auburn University · Benuvia Therapeutics Inc. · Biopharmaceutical Research Company · Bod Australia · Brigham and Women's Hospital · Cambridge Cognition Ltd · Cambridgeshire and Peterborough NHS Foundation Trust · Canopy Growth Corporation · Castleton University · Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Charite University, Berlin, Germany · Colorado Department of Public Health and Environment · Faneca 66 Foundation · Foundation for Orthopaedic Research and Education · Geha Mental Health Center · Glostrup University Hospital, Copenhagen · Hartford Hospital · Heidelberg University · Hospital General Universitario Gregorio Marañon · Hospitales Universitarios Virgen del Rocío · Massachusetts General Hospital · Mayo Clinic · Medical University of Silesia · Medical University of Vienna · Murdoch Childrens Research Institute · National Football League · National Institute of Mental Health (NIMH) · National Institutes of Health (NIH) · National and Kapodistrian University of Athens · Orcosa Inc. · Oxford Health NHS Foundation Trust · Psychiatric University Hospital, Zurich · all 314 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) EPIDIOLEX — 2020-07-31 – 2023-10-20 fda.gov ↗
Approved EU (EMA) Epidyolex — 2019-09-19 europa.eu ↗
Approved US (FDA) EPIDIOLEX — 2018-06-25 fda.gov ↗

Trials 316 · started per year

today
US approved 2018
EU approved 2019
1
2
1
1
2
2
4
3
10
14
10
14
16
21
26
41
40
21
31
26
23
1
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049205020512052
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 021 trials
Phase 0 NCT05650697 Sep 2026 → Dec 2027 expected — University of Oklahoma Not yet recruiting No outcome recorded
Phase 0 NCT07434895 Jul 2026 → Dec 2029 expected substance abuse Hannah Harris Recruiting No outcome recorded
Phase 0 NCT04855526 Dec 2025 → Dec 2026 expected cannabis dependence Hartford Hospital Not yet recruiting No outcome recorded
Phase 0 NCT07167446 Oct 2025 → Sep 2027 expected chemotherapy-induced neuropathy, colorectal cancer Fox Chase Cancer Center Recruiting No outcome recorded
Phase 0 NCT06617247 Dec 2024 → Dec 2026 expected burn goodship syndrome University of Sao Paulo Not yet recruiting No outcome recorded
Phase 0 NCT05283382 Oct 2024 → Dec 2026 expected anxiety University of Connecticut Recruiting No outcome recorded
Phase 0 NCT05672342 Jul 2024 → Oct 2025 breast carcinoma, chemotherapy-induced neuropathy, colon carcinoma City of Hope Medical Center Withdrawn No outcome recorded
Phase 0 NCT06692933 Jun 2024 → Aug 2027 expected — Washington State University Recruiting No outcome recorded
Phase 0 NCT06123702 Apr → Dec 2024 social phobia Hartford Hospital Unknown No outcome recorded
Phase 0 NCT05934500 Oct 2023 → Jul 2025 — Foundation for Orthopaedic Research and Education Unknown No outcome recorded
Phase 152 trials
Phase 1 NCT06148038 Sep 2026 → Mar 2028 expected breast cancer Medical University of South Carolina Recruiting No outcome recorded
Phase 1 NCT05067387 Jul 2026 → Jun 2027 expected drug-induced mental disorder, substance abuse University of California, Los Angeles Not yet recruiting No outcome recorded
Phase 1 NCT06129591 May 2026 → Jul 2027 expected — University of Oklahoma Not yet recruiting No outcome recorded
Phase 1 NCT06222268 Mar 2026 → Sep 2031 expected post-traumatic stress disorder Wayne State University Not yet recruiting No outcome recorded
Phase 1 NCT06362889 Dec 2025 overdue acne Rejuva Medical Aesthetics Not yet recruiting No outcome recorded
Phase 1 NCT07233239 Nov 2025 → Nov 2027 expected focal epilepsy Jazz Pharmaceuticals Recruiting No outcome recorded
Phase 1 NCT07146945 Aug 2025 → Feb 2026 overdue — Delphian Therapeutics Australia Pty, Ltd Not yet recruiting No outcome recorded
Phase 1 NCT07001930 Aug 2025 → Sep 2029 expected nicotine dependence Johns Hopkins University Recruiting No outcome recorded
Phase 1 NCT07027566 Jul 2025 → May 2026 overdue dentin sensitivity Federal University of Pará Not yet recruiting No outcome recorded
Phase 1 NCT06854783 Jul → Oct 2025 — Tiamat Australia Pty Ltd Completed No outcome recorded
Phase 1/226 trials
Phase 1/2 NCT07696871 Jun → Dec 2026 expected major depressive disorder University of Southern Santa Catarina Recruiting No outcome recorded
Phase 1/2 NCT07592390 May → Dec 2026 expected attention deficit-hyperactivity disorder University of Southern Santa Catarina Recruiting No outcome recorded
Phase 1/2 NCT07298408 Apr → Dec 2026 expected diabetic polyneuropathy Florida A&M University Recruiting No outcome recorded
Phase 1/2 NCT07278505 Oct 2025 → Feb 2030 expected — Icahn School of Medicine at Mount Sinai Recruiting No outcome recorded
Phase 1/2 NCT06381180 Sep 2025 → Dec 2030 expected cannabis dependence, post-traumatic stress disorder Wayne State University Not yet recruiting No outcome recorded
Phase 1/2 NCT06738732 Jan 2025 → Jan 2027 expected Dravet syndrome, Lennox-Gastaut syndrome Alexander Rotenberg Not yet recruiting No outcome recorded
Phase 1/2 NCT06099379 Jun 2024 → Jul 2026 overdue cannabis dependence, thrombocytopenia 3 University of Montreal Hospital Centre (CHUM) Recruiting No outcome recorded
Phase 1/2 NCT06381791 May 2024 → Dec 2026 expected osteoarthritis, rotator cuff syndrome The Methodist Hospital Research Institute Recruiting No outcome recorded
Phase 1/2 NCT05885542 Nov 2023 → Jul 2028 expected cannabis dependence Medical University of South Carolina Recruiting No outcome recorded
Phase 1/2 NCT03529448 Aug 2023 → Nov 2025 glioblastoma Grupo Español de Investigación en Neurooncología Completed No outcome recorded
Phase 2121 trials
Phase 2 NCT03883360 Jan → Feb 2050 schizophrenia University of Maryland, Baltimore Withdrawn No outcome recorded
Phase 2 NCT07527338 Jul 2026 → Feb 2031 expected alcohol abuse University of Colorado, Boulder Not yet recruiting No outcome recorded
Phase 2 NCT07624279 Jun 2026 → Jul 2027 expected headache disorder American Society of Pain and Neuroscience, Inc. Not yet recruiting No outcome recorded
Phase 2 NCT07549256 Jun 2026 → May 2028 expected castration-resistant prostate carcinoma Regionshospital Nordjylland Not yet recruiting No outcome recorded
Phase 2 NCT07564245 May 2026 → May 2029 expected — Assistance Publique - Hôpitaux de Paris Not yet recruiting No outcome recorded
Phase 2 NCT07279558 Mar 2026 → Aug 2029 expected alcohol-related disorders University of Colorado, Denver Recruiting No outcome recorded
Phase 2 NCT07570472 Mar → May 2026 overdue sleep disorder KU Leuven Recruiting No outcome recorded
Phase 2 NCT06840899 Feb 2026 → May 2027 expected spinal cord injury University of Wisconsin, Madison Recruiting No outcome recorded
Phase 2 NCT07199218 Oct 2025 → Dec 2027 expected autism Bazelet Nehushtan LtD. Recruiting No outcome recorded
Phase 2 NCT06731894 Oct 2025 → Jan 2028 expected breast carcinoma, chemotherapy-induced neuropathy, colon carcinoma City of Hope Medical Center Recruiting No outcome recorded
Show all 121 trials opens the full record — a long page
Phase 2/318 trials
Phase 2/3 NCT07552974 Jun 2026 → Feb 2027 expected — Associação Pan-Americana Multidisciplinar de Endocanabinologia Not yet recruiting No outcome recorded
Phase 2/3 NCT06333041 Apr 2026 → Apr 2027 expected mucopolysaccharidosis type 3 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Recruiting No outcome recorded
Phase 2/3 NCT06514066 Sep 2024 → Oct 2025 overdue vascular dementia Hospital Pengajar Universiti Putra Malaysia Not yet recruiting No outcome recorded
Phase 2/3 NCT05562635 Jul 2023 bruxism, myofascial pain syndrome, temporomandibular joint disorder Medical University of Silesia Unknown No outcome recorded
Phase 2/3 NCT05020028 Jun 2022 → Sep 2027 expected osteoarthritis, knee NYU Langone Health Recruiting No outcome recorded
Phase 2/3 NCT05283161 Apr → Aug 2022 fibromyalgia FG Brasil LTDA Unknown No outcome recorded
Phase 2/3 NCT04615949 Apr 2021 → Nov 2022 COVID-19, cardiovascular disorder Cardiol Therapeutics Inc. Terminated No outcome recorded
Phase 2/3 NCT04387617 Feb 2021 → Jan 2022 urolithiasis Mayo Clinic Completed No outcome recorded
Phase 2/3 NCT04775030 Jan 2021 → Jan 2022 temporomandibular joint disorder Medical University of Silesia Unknown No outcome recorded
Phase 2/3 NCT04672252 Dec 2020 → Dec 2021 neuropathy, painful NYU Langone Health Completed No outcome recorded
Phase 339 trials
Phase 3 NCT07148206 Oct 2026 → May 2028 expected opiate dependence Montefiore Medical Center Not yet recruiting No outcome recorded
Phase 3 NCT07326124 Jun 2026 → Sep 2028 expected treatment-refractory schizophrenia University of Oxford Not yet recruiting No outcome recorded
Phase 3 NCT06778564 Feb 2026 → Feb 2028 expected psychotic disorder University of Oxford Not yet recruiting No outcome recorded
Phase 3 NCT07245238 Nov 2025 → Dec 2027 expected systemic sclerosis Khon Kaen University Recruiting No outcome recorded
Phase 3 NCT07123467 Nov 2025 → Aug 2027 expected generalized anxiety disorder Wayne State University Recruiting No outcome recorded
Phase 3 NCT06940674 Jun 2025 → Jul 2027 expected substance-related disorder Icahn School of Medicine at Mount Sinai Recruiting No outcome recorded
Phase 3 NCT05840822 May 2024 → Sep 2027 expected insomnia Avecho Biotechnology Active not recruiting No outcome recorded
Phase 3 NCT06099171 Feb → Sep 2024 — Humanitas Clinical and Research Center Unknown No outcome recorded
Phase 3 NCT05867849 Oct 2023 → Dec 2029 expected bipolar disorder University of British Columbia Recruiting No outcome recorded
Phase 3 NCT03825965 May 2023 → Feb 2025 osteoarthritis, knee McMaster University Completed No outcome recorded
Phase 414 trials
Phase 4 NCT06924827 Jun 2026 → Jun 2028 expected Dravet syndrome, Lennox-Gastaut syndrome Elizabeth Donner Not yet recruiting No outcome recorded
Phase 4 NCT05864846 Jun 2023 → Apr 2026 tuberous sclerosis Jazz Pharmaceuticals Completed No outcome recorded
Phase 4 NCT04749628 Nov 2022 → Oct 2024 neuropathy, painful, osteoarthritis, knee, substance-related disorder Hospital for Special Surgery, New York Completed No outcome recorded
Phase 4 NCT05209867 May → Dec 2022 unexplained long-lasting fever/inflammatory syndrome University of Florida Completed No outcome recorded
Phase 4 NCT05324449 Apr 2022 → Mar 2025 anxiety, epilepsy Hugo W. Moser Research Institute at Kennedy Krieger, Inc. Completed No outcome recorded
Phase 4 NCT04899050 Jul 2021 → May 2023 — University of South Florida Completed No outcome recorded
Phase 4 NCT05044819 Jul 2021 → Aug 2027 expected Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis Jazz Pharmaceuticals Active not recruiting No outcome recorded
Phase 4 NCT04997954 May 2021 → Jun 2023 amyotrophic lateral sclerosis Gold Coast Hospital and Health Service Unknown No outcome recorded
Phase 4 NCT05022186 Apr 2021 → Dec 2022 cognitive impairment with or without cerebellar ataxia Aristotle University Of Thessaloniki Unknown No outcome recorded
Phase 4 NCT04603391 Feb → Dec 2021 — University of Florida Completed No outcome recorded
Phase not applicable18 trials
— NCT07471347 Mar → Dec 2026 expected psychiatric disorder King's College London Not yet recruiting No outcome recorded
— NCT07445568 Sep 2025 osteoarthritis, knee Universidad del Valle de México, Campus Cuernavaca Completed No outcome recorded
— NCT05456113 Dec 2024 → Dec 2025 — Penn State University Withdrawn No outcome recorded
— NCT07162454 Nov 2024 → May 2025 diabetic polyneuropathy Universidad Complutense de Madrid Completed No outcome recorded
— NCT05351905 Nov 2022 → Dec 2025 chronic pain syndrome University Health Network, Toronto Completed No outcome recorded
— NCT06217146 Oct 2022 → Mar 2024 Alzheimer disease, disruptive behavior disorder M. H MediCane Ltd. Terminated No outcome recorded
— NCT04376437 Mar → Dec 2022 chemotherapy-induced neuropathy HaEmek Medical Center, Israel Unknown No outcome recorded
— NCT04831294 Jul 2021 → May 2022 — Auburn University Unknown No outcome recorded
— NCT04605393 Jan 2021 → Jul 2023 cannabis dependence, schizophrenia King's College London Completed No outcome recorded
— NCT04851392 Mar 2019 → Jun 2021 cannabis dependence University College, London Completed No outcome recorded
Phase not stated7 trials
— NCT02397863 Dec 2014 → Dec 2019 epilepsy Augusta University Available No outcome recorded
— NCT02660255 — epilepsy University of Nebraska Approved for marketing No outcome recorded
— NCT02556008 — epilepsy University of California, Los Angeles No longer available No outcome recorded
— NCT03014440 — epilepsy Eric Marsh, MD No longer available No outcome recorded
— NCT02461706 — epilepsy University of Florida No longer available No outcome recorded
— NCT03196934 — epilepsy MultiCare Health System Research Institute No longer available No outcome recorded
— NCT03676049 — epilepsy John Available No outcome recorded
Also used as a comparator or background therapy in 62 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT06137027 Comparator Sep 2023 → Jan 2024 — The University of The West Indies Unknown No outcome recorded
Phase 0 NCT04587791 Comparator Dec 2021 → Aug 2026 overdue chronic pain syndrome, substance-related disorder Yale University Recruiting No outcome recorded
Phase 0 NCT05076370 Comparator Dec 2021 → Jun 2024 substance dependence Yale University Completed No outcome recorded
Phase 0 NCT04044729 Comparator Mar 2020 → Dec 2024 chronic pain syndrome University of Utah Completed No outcome recorded
Phase 0 NCT03215940 Comparator Feb 2018 → Dec 2024 chronic pain syndrome University of Utah Completed No outcome recorded
Phase 19 trials
Phase 1 NCT07462559 Comparator Mar → Dec 2026 expected — Helsinki University Central Hospital Not yet recruiting No outcome recorded
Phase 1 NCT06859710 Comparator Nov 2025 → Sep 2027 expected pain agnosia, substance abuse University of California, Los Angeles Recruiting No outcome recorded
Phase 1 NCT06686914 Comparator Jun 2025 → Dec 2028 expected — West Virginia University Recruiting No outcome recorded
Phase 1 NCT06574100 Comparator Oct 2024 → Nov 2025 overdue — University of Saskatchewan Recruiting No outcome recorded
Phase 1 NCT06192589 Comparator Feb → Sep 2024 drug-induced liver injury Food and Drug Administration (FDA) Completed No outcome recorded
Phase 1/27 trials
Phase 1/2 NCT06930703 Comparator Apr 2025 → Feb 2027 expected sickle cell disease Icahn School of Medicine at Mount Sinai Recruiting No outcome recorded
Phase 1/2 NCT06414473 Comparator Jun 2024 → Dec 2026 expected osteoarthritis, knee University of Florida Recruiting No outcome recorded
Phase 1/2 NCT05132699 Comparator Apr 2022 → Jun 2023 post-traumatic stress disorder The University of Texas Health Science Center at San Antonio Completed No outcome recorded
Phase 1/2 NCT04760613 Comparator Feb 2022 → Jun 2023 radiculopathy NYU Langone Health Completed No outcome recorded
Phase 1/2 NCT03904849 Comparator Oct 2019 → Apr 2020 alcohol-related disorders Medical University of South Carolina Withdrawn No outcome recorded
Phase 225 trials
Phase 2 NCT06569394 Comparator Dec 2024 → Jun 2028 expected cannabis dependence University of Colorado, Denver Recruiting No outcome recorded
Phase 2 NCT06575751 Comparator Dec 2024 → Jun 2028 expected cannabis dependence University of Colorado, Denver Recruiting No outcome recorded
Phase 2 NCT06629389 Comparator Nov 2024 → Nov 2025 overdue Parkinson disease Laboratorio Elea Phoenix S.A. Recruiting No outcome recorded
Phase 2 NCT06218056 Comparator Oct 2024 → Dec 2026 expected nicotine dependence University of California, Los Angeles Recruiting No outcome recorded
Phase 2 NCT06542445 Comparator Aug 2024 → Aug 2026 overdue attention deficit-hyperactivity disorder Bazelet Nehushtan LtD. Recruiting No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT07148843 Comparator Aug 2026 → Oct 2030 expected alcohol withdrawal, alcohol-related disorders Johns Hopkins University Not yet recruiting No outcome recorded
Phase 2/3 NCT05613608 Comparator Apr 2023 → Apr 2027 expected alcohol-related disorders University of Colorado, Denver Recruiting No outcome recorded
Phase 2/3 NCT04989413 Comparator Oct 2022 → Feb 2025 migraine disorder Hospital Israelita Albert Einstein Terminated No outcome recorded
Phase 2/3 NCT04423341 Comparator May 2020 → Mar 2021 benign essential blepharospasm Silkiss Eye Surgery Completed No outcome recorded
Phase 34 trials
Phase 3 NCT07434973 Comparator May 2026 → Dec 2029 expected early-onset schizophrenia University of Oxford Not yet recruiting No outcome recorded
Phase 3 NCT06708299 Comparator Apr 2025 → Sep 2026 expected pericarditis Cardiol Therapeutics Inc. Recruiting No outcome recorded
Phase 3 NCT07668856 Comparator Feb 2025 → Nov 2027 expected epilepsy UMC Utrecht Recruiting No outcome recorded
Phase 3 NCT04527003 Comparator Dec 2020 → May 2024 endometriosis Milton S. Hershey Medical Center Terminated No outcome recorded
Phase 43 trials
Phase 4 NCT05649059 Comparator Jul 2025 → May 2026 overdue social phobia Massachusetts Institute of Technology Recruiting No outcome recorded
Phase 4 NCT04768478 Comparator Oct 2021 → Oct 2023 — NYU Langone Health Withdrawn No outcome recorded
Phase 4 NCT04732169 Comparator Jul 2021 — University of Alabama at Birmingham Withdrawn No outcome recorded
Phase not applicable5 trials
— NCT07656350 Comparator Jun 2026 → Dec 2027 expected — King's College London Recruiting No outcome recorded
— NCT04059978 Comparator May → Oct 2020 allesthesia University Hospital, Basel, Switzerland Completed No outcome recorded
— NCT03985995 Comparator Sep → Dec 2019 allesthesia University Hospital, Basel, Switzerland Completed No outcome recorded
— NCT03224468 Comparator Jul 2017 → Feb 2021 anxiety, depressive disorder, insomnia Massachusetts General Hospital Completed No outcome recorded
— NCT02249299 Comparator Aug 2014 → Jun 2015 attention deficit-hyperactivity disorder King's College London Completed No outcome recorded

Evidence & citations 45 cited values

Every value below carries the sentence it was read from. 408 sources stand behind the page.

FieldValueCited text
Known as cannabidiol “acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic...” NCT04855526 ↗
327

“Concurrent lines of evidence suggest that targeting the endocannabinoid (eCB) system by administration of cannabidiol (CBD) could upregulate GABAergic functions and correct...” NCT06261450 ↗

“GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added...” NCT02091375 ↗

“The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non...” NCT06924827 ↗

“A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗

“Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗

“Many physically-active Americans have begun using cannabidiol (CBD) for pain relief and improved recovery time, and CBD is of particular interest due to its positive safety...” PMID 41918004 ↗ Mar 2026

“Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic...” NCT06353828 ↗

“stimulation of the endocannabinoid (eCB) system with the administration of Cannabidiol (CBD) could upregulate GABAergic function and correct inhibitory deficits presumed...” NCT06261502 ↗

“This is a preliminary study designed to assess the safety and properties of a new oral formulation containing the two most common cannabinoids used for medicinal purposes -...” NCT03936907 ↗

“This Phase I randomized controlled trial aimed to assess the safety and tolerability of cannabidiol (CBD) and alcohol co-administration among moderate alcohol consumers in...” PMID 42288934 ↗ Jun 2026

“Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic,...” NCT07552974 ↗

“Full-spectrum Cannabis sativa extract containing cannabidiol (CBD) 100 mg/mL and tetrahydrocannabinol (THC) 3.33 mg/mL, administered sublingually for 12 weeks according to a...” NCT07696871 ↗

“oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener...” NCT04421456 ↗

“Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in...” NCT01606137 ↗

“More recently, there's been considerable excitement in the press over the potential therapeutic use of cannabidiol (CBD) products in the treatment of a variety of physical and...” NCT04197102 ↗

“The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced...” NCT04398446 ↗

“Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg...” NCT03005119 ↗

“Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses.” NCT07199218 ↗

“Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water” NCT03627117 ↗

“A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults” NCT02224690 ↗

“Cannabidiol (CBD) has been approved as a treatment for rare childhood epilepsies and could be an effective treatment for psychotic disorders, anxiety disorders and addictions.” NCT05032807 ↗

“The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Ankle and Tibia Fracture Open Reduction and Internal Fixation. A Double-Blind, Randomized Control Study” NCT04768478 ↗

“The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain.” NCT05076370 ↗

“A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet” NCT05766969 ↗

“Cannabidiol (CBD) is the active ingredient of interest because of its anti-inflammatory effects and lack of psychoactive effects seen with tetrahydrocannabinol (THC).” NCT03825965 ↗

“Single subject repeated measures design of an open label administration of Cannabidiol (CBD) to 5 participants withdrawing from cannabis use in an inpatient setting.” NCT02083874 ↗

“Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumour effect with temozolomide and radiotherapy in preclinical glioma models.” NCT03529448 ↗

“The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects.” NCT02283281 ↗

“GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring” NCT04252586 ↗

“Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).” NCT02249299 ↗

“BACKGROUND: Cannabidiol (CBD) has been shown recently to positively affect patient pain and satisfaction immediately after arthroscopic rotator cuff repair (ARCR).” PMID 38322981 ↗ Feb 2024

“Cannabinoids such as cannabidiol (CBD) exhibit anti-inflammatory properties and have the potential to act as a therapeutic following mild traumatic brain injury.” PMID 39266961 ↗ Sep 2024

“Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients” NCT04439955 ↗

“It is therefore important to carry out studies to better understand the efficacy Δ-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) on MS symptoms .” NCT05092191 ↗

“A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability.” PMID 42204954 ↗ May 2026

“A Triple-blind, Placebo-controlled, Randomized, Crossover Study of Low Dose Oral Synthetic Cannabidiol Effects in Healthy Cannabis Occasional Users” NCT05407285 ↗

“This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder.” NCT06512389 ↗

“Prior work indicates that cannabidiol (CBD) might reduce inflammation; however, the genetics underpinning of this effect are not well investigated.” PMID 38252549 ↗ Jan 2024

“Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.” NCT05184478 ↗

“ZYN002, a pharmaceutically manufactured cannabidiol, formulated as a clear gel that can be applied to the skin (called transdermal delivery)” NCT04977986 ↗

“This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety” PMID 31109198 ↗ May 2019

“The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil.” NCT05644262 ↗

“The Safety and Efficacy of Treatment With Cannabidiol (CBD) Oil Enriched With Terpenes, Devoid of THC, in Children Diagnosed With ADHD” NCT06542445 ↗

“oral tablet formulation of natural Cannabidiol (CBD) at 40 mg and 100 mg alone and in combination with Tetrahydrocannabinol (THC)” NCT04226690 ↗

“Cannabidiol (CBD) is increasingly used for pain management, including in transplant recipients with limited analgesic options.” PMID 41252210 ↗ Nov 2025

“Some evidence indicates that cannabidiol (CBD), a non-intoxicating cannabis component, might mitigate certain effects of THC.” NCT06859710 ↗

“Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.” NCT04721691 ↗

“An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis” NCT01610713 ↗

“A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.” NCT04088929 ↗

“Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are two naturally occurring phytocannabinoids found in cannabis.” NCT05121506 ↗

“A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)” NCT02544763 ↗

“cannabis oils containing tetrahydrocannabinol (THC) and cannabidiol (CBD) consumed orally in people living with HIV” PMID 30659041 ↗ Jan 2019

“determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants” NCT04436081 ↗

“The two active cannabinoids of interest in this trial are tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD).” NCT03635593 ↗

“Evaluation of the efficacy of the occlusal appliance with active cannabidiol (CBD) molecules in TMD patients” NCT04775030 ↗

“hemp-derived cannabidiol (CBD) and terpenes produced as a potential sleep aid for people with insomnia.” NCT05233761 ↗

“co-administration of two constituents of cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” PMID 40611810 ↗ Jul 2025

“Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD” NCT06014424 ↗

“This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in adults.” NCT04286594 ↗

“add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay” NCT05860699 ↗

“Women were randomized 1:1 to cannabidiol (CBD) vs. delta-9-tetrahydrocannabinol (THC) balms.” PMID 41467893 ↗ Dec 2025

“MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation” NCT05351905 ↗

“a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A)” NCT05049733 ↗

“what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance” NCT06129591 ↗

“each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.” NCT03875261 ↗

“Cannabidiol (CBD) exhibits analgesic, myorelaxant, and anti-inflammatory properties” PMID 41517391 ↗ Dec 2025

“Preclinical studies have demonstrated the analgesic potential of cannabidiol (CBD).” PMID 34086631 ↗ Jan 2022

“These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).” NCT00397605 ↗

“S1-221 is a liquid containing cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC).” NCT07146945 ↗

“Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).” NCT06615284 ↗

“new CBD granules formulation (GLA-015 / Cannabidiol 1500 mg 29,7% w/w GRA BLD P)” NCT04790136 ↗

“A Phase 1a "Window Trial" of Cannabidiol (CBD) For Breast Cancer Primary Tumors” NCT06148038 ↗

“Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).” NCT03805750 ↗

“Single-dose 20.0 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic.” NCT04816994 ↗

“varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD)” NCT05037487 ↗

“transdermal cannabidiol (CBD) delivered using GT4 skin bream technology” NCT06738732 ↗

“cannabidiol (CBD) can sometimes attenuate or exacerbate the effects of” PMID 36780161 ↗ Feb 2023

“the non- tetrahydrocannabinol (THC) and cannabidiol (CBD) cannabinoids” PMID 26883879 ↗ Jul 2016

“Participants in this arm will receive Cannabidiol (CBD) for 12 weeks.” NCT07326124 ↗

“Each mL of MediCabilis provides: * 50 mg of Cannabidiol (CBD+CBDA)” NCT04997954 ↗

“oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” NCT05067387 ↗

“received a topical cream containing cannabidiol and 10% urea” NCT07162454 ↗

“1600mg cannabidiol, single oral dose (8 ml oily solution)” NCT04059978 ↗

“Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil” NCT06362889 ↗

“Cannabidiol (CBD) is a glial inhibitor in animal models” PMID 36123113 ↗ Sep 2022

“FDA-approved cannabinoid cannabidiol (CBD; Epidiolex)” NCT04036968 ↗

“adding cannabidiol (CBD) to the existing treatment” NCT06778564 ↗

“RLS103 (cannabidiol \[CBD\] inhaled dry powder)” NCT05429788 ↗

“hemp-based Cannabidiol (CBD) topical products” NCT04741477 ↗

“RLS103 (Inhaled Dry Powder Cannabidiol [CBD])” NCT05678881 ↗

“oral cannabidiol (CBD; 0, 200, 400, 800 mg)” NCT01844687 ↗

“exposed to Δ9-THC and cannabidiol (CBD)” NCT05306249 ↗

“Twice daily 100mg cannabidiol (CBD)” NCT06840899 ↗

“multiple doses of Cannabidiol (CBD)” NCT03840512 ↗

“Epidiolex (cannabidiol) (CBD)” NCT04732169 ↗

“Epidiolex (cannabidiol)” NCT06381791 ↗

“300mg cannabidiol oil” NCT07656350 ↗

“cannabidiol (CBD)” NCT03832816 ↗

“Cannabidiol (CBD)” NCT04283019 ↗

“Oral cannabidiol” NCT07001930 ↗

“Cannabidiol” NCT06234631 ↗

NCT05942911 ↗

NCT05646459 ↗

NCT06213233 ↗

NCT06672666 ↗

NCT04396730 ↗

NCT05170217 ↗

NCT02088060 ↗

NCT06629389 ↗

NCT06578455 ↗

NCT05613608 ↗

NCT03693833 ↗

NCT02324673 ↗

NCT00628290 ↗

NCT07462559 ↗

NCT05022186 ↗

NCT04590495 ↗

NCT04731116 ↗

NCT05020028 ↗

NCT04749628 ↗

NCT05672342 ↗

NCT03196934 ↗

NCT03883360 ↗

NCT05023070 ↗

NCT04754399 ↗

NCT02783092 ↗

NCT06940674 ↗

NCT03355300 ↗

NCT04731779 ↗

NCT02751359 ↗

NCT02051387 ↗

NCT06108349 ↗

NCT04105231 ↗

NCT03582137 ↗

NCT05044819 ↗

NCT05232123 ↗

NCT04044729 ↗

NCT05445804 ↗

NCT06107062 ↗

NCT04989413 ↗

NCT03471559 ↗

NCT06477406 ↗

NCT05885542 ↗

NCT04482244 ↗

NCT05283161 ↗

NCT05283382 ↗

NCT05253417 ↗

NCT05822362 ↗

NCT04899050 ↗

NCT04615949 ↗

NCT04760613 ↗

NCT03467620 ↗

NCT04873453 ↗

NCT05649059 ↗

NCT03102918 ↗

NCT04527003 ↗

NCT05864846 ↗

NCT03310593 ↗

NCT04349930 ↗

NCT07279558 ↗

NCT02044809 ↗

NCT03607643 ↗

NCT01596075 ↗

NCT02556008 ↗

NCT06845124 ↗

NCT05016349 ↗

NCT06290063 ↗

NCT05240755 ↗

NCT04587791 ↗

NCT03336242 ↗

NCT02478424 ↗

NCT06099379 ↗

NCT02548559 ↗

NCT02461706 ↗

NCT05840822 ↗

NCT03891264 ↗

NCT05015439 ↗

NCT06099171 ↗

NCT06514066 ↗

NCT07668856 ↗

NCT04129489 ↗

NCT05650697 ↗

NCT07245238 ↗

NCT06192589 ↗

NCT05867849 ↗

NCT06381180 ↗

NCT02255292 ↗

NCT02504151 ↗

NCT05388058 ↗

NCT03458416 ↗

NCT03676049 ↗

NCT05498012 ↗

NCT06686914 ↗

NCT01385124 ↗

NCT04447846 ↗

NCT06137027 ↗

NCT03014440 ↗

NCT07278505 ↗

NCT02660255 ↗

NCT07527338 ↗

NCT02286986 ↗

NCT05387148 ↗

NCT05651607 ↗

NCT02112292 ↗

NCT04550377 ↗

NCT01502046 ↗

NCT07445568 ↗

NCT05742724 ↗

NCT03787628 ↗

NCT06617247 ↗

NCT04613102 ↗

NCT02318537 ↗

NCT02318563 ↗

NCT02318602 ↗

NCT05679830 ↗

NCT04520685 ↗

NCT07434973 ↗

NCT05571592 ↗

NCT03421496 ↗

NCT06569394 ↗

NCT01311778 ↗

NCT06930703 ↗

NCT04585841 ↗

NCT01605539 ↗

NCT04911127 ↗

NCT05456113 ↗

NCT06731894 ↗

NCT03518801 ↗

NCT05002114 ↗

NCT01037322 ↗

NCT06692933 ↗

NCT05823753 ↗

NCT05753007 ↗

NCT07148843 ↗

NCT03252756 ↗

NCT02487381 ↗

NCT04821856 ↗

NCT04193631 ↗

NCT05934500 ↗

NCT04883255 ↗

NCT03984565 ↗

NCT01180374 ↗

NCT02332655 ↗

NCT05457465 ↗

NCT05317546 ↗

NCT07027566 ↗

NCT07624279 ↗

NCT04411225 ↗

NCT04878627 ↗

NCT02551731 ↗

NCT05803434 ↗

NCT00309413 ↗

NCT06206291 ↗

NCT03467113 ↗

NCT06695195 ↗

NCT07298408 ↗

NCT04192370 ↗

NCT07549256 ↗

NCT02932605 ↗

NCT06123702 ↗

NCT04271917 ↗

NCT04777643 ↗

NCT04851392 ↗

NCT02902081 ↗

NCT06266611 ↗

NCT02397863 ↗

NCT06574100 ↗

NCT05269706 ↗

NCT03802799 ↗

NCT07570472 ↗

NCT05159830 ↗

NCT05269628 ↗

NCT05269459 ↗

NCT07123467 ↗

NCT05600114 ↗

NCT04603391 ↗

NCT03549819 ↗

NCT02559167 ↗

NCT04582591 ↗

NCT05632627 ↗

NCT04423341 ↗

NCT06222268 ↗

NCT04387617 ↗

NCT04831294 ↗

NCT06854783 ↗

NCT07471347 ↗

NCT02926859 ↗

NCT04978428 ↗

NCT04992624 ↗

NCT07434895 ↗

NCT03904849 ↗

NCT04605393 ↗

NCT04729179 ↗

NCT02818777 ↗

NCT05132699 ↗

NCT04467918 ↗

NCT06448923 ↗

NCT03941288 ↗

NCT02492074 ↗

NCT04205682 ↗

NCT06575751 ↗

NCT04056442 ↗

NCT05299944 ↗

NCT05097651 ↗

NCT02392780 ↗

NCT02291562 ↗

NCT02291536 ↗

NCT06218056 ↗

NCT04982029 ↗

NCT04607603 ↗

NCT00588731 ↗

NCT04567784 ↗

NCT02815540 ↗

NCT07564245 ↗

NCT06074172 ↗

NCT03248167 ↗

NCT00916201 ↗

NCT03634189 ↗

NCT04611438 ↗

NCT04504877 ↗

NCT04267679 ↗

NCT05324449 ↗

NCT02844933 ↗

NCT06414473 ↗

NCT03215940 ↗

NCT03164512 ↗

NCT04609748 ↗
Known as ATL5 “ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule).” NCT06218056 ↗
Known as AVCN583601 “3% Cannabidiol cream (AVCN583601)” NCT04613102 ↗
Known as BRC-001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06538389 ↗
Known as BRC-003 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06523725 ↗
Known as Broad Spectrum Cannabidiol “Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06569394 ↗
1

“Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06575751 ↗
Known as Broad-Spectrum Cannabidiol (CBD) “Broad-Spectrum Cannabidiol (CBD)” NCT07279558 ↗
Known as bsCBD “Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used” NCT06290063 ↗
2

“Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06569394 ↗

“Broad Spectrum Cannabidiol (bsCBD) 400 mg” NCT06575751 ↗
Known as BTX 1204 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824405 ↗
Known as BTX 1503 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03573518 ↗
Known as Cannabidiol (CBD) ClinicalTrials.gov intervention name — accepted as the source's own label NCT07167446 ↗
Known as cannabidiol extract ClinicalTrials.gov intervention name — accepted as the source's own label NCT04280289 ↗
Known as Cannabidiol Oil “Drug: Cannabidiol Oil” NCT06514066 ↗
Known as Cannabidiol Oral Solution “A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms” NCT03421496 ↗
Known as CardiolRx ClinicalTrials.gov intervention name — accepted as the source's own label NCT06708299 ↗
2

NCT05494788 ↗

NCT05180240 ↗
Known as CardiolRxTM “CardiolRxTM (cannabidiol [CBD] solution), which is known to have anti-inflammatory properties, is being investigated to treat the underlying inflammatory process and thereby...” NCT05180240 ↗
Known as CBD “The investigators propose to study the effects of cannabidiol (CBD) on cardiac electrical function and the autonomic nervous system in children with Dravet syndrome (DS) and...” NCT02815540 ↗
192

“For many years, persons with MS (PwMS) have used cannabis to relax, to reduce pain and spasticity, or to improve sleep and daily functioning, despite the lack of scientific...” PMID 39114536 ↗ Jul 2024

“This study seeks to exploit bladder cannabidiol receptors as a therapeutic drug target by conducting a double-masked, placebo-controlled randomized trial evaluating the effects...” NCT04349930 ↗

“The primary purpose of this study was to evaluate the efficacy, safety, and tolerability of Cannabidiol Oral Solution (CBD) as adjunctive therapy with vigabatrin as initial...” NCT03421496 ↗

“The non-psychoactive phytocannabinoid cannabidiol (CBD) has attracted considerable attention due to its lack of abuse potential, its excellent safety profile, its unique and...” NCT03252756 ↗

“Previous research has indicated that cannabinoids including cannabidiol (CBD), delta-9 tetrahydrocannabinol (THC), and a number of other cannabinoids may hold potential for...” NCT06477406 ↗

“The purpose of this study is to assess how Cannabidiol (CBD) impacts the effectiveness of oral contraceptive (birth control) pills and if CBD changes the possible side effects...” NCT04396730 ↗

“Concurrent lines of evidence suggest that targeting the endocannabinoid (eCB) system by administration of cannabidiol (CBD) could upregulate GABAergic functions and correct...” NCT06261450 ↗

“This is a multi-center study to evaluate the efficacy and safety of Cannabidiol Oral Solution (CBD) in the treatment of children aged 6 months through 36 months with a...” NCT02551731 ↗

“The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non...” NCT06924827 ↗

“GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added...” NCT02091375 ↗

“Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment...” PMID 29619533 ↗ Apr 2018

“Cannabidiol (CBD), derived from the Cannabis sativa plant, is being investigated for its potential health benefit without the psychoactive properties and adverse reactions that...” NCT06578455 ↗

“A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789 ↗

“Full-spectrum Cannabis sativa extract containing cannabigerol (CBG) 30 mg/mL, cannabidiol (CBD) 30 mg/mL, and tetrahydrocannabinol (THC) 3 mg/mL, administered sublingually for...” NCT07592390 ↗

“Many physically-active Americans have begun using cannabidiol (CBD) for pain relief and improved recovery time, and CBD is of particular interest due to its positive safety...” PMID 41918004 ↗ Mar 2026

“Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa, possesses potent immunomodulatory and anti-inflammatory properties as described in both acute and chronic...” NCT06353828 ↗

“Cannabidiol (CBD), a non-addictive and non-psychotropic cannabis component stands out as a potential therapeutic agent, given its analgesic and anti-inflammatory properties as...” PMID 39979051 ↗ Feb 2025

“stimulation of the endocannabinoid (eCB) system with the administration of Cannabidiol (CBD) could upregulate GABAergic function and correct inhibitory deficits presumed...” NCT06261502 ↗

“This study will test if Cannabidiol (CBD) therapy is safe in humans and reduces the number and/or severity of seizures in patients with drug resistant epilepsy when taken in...” NCT02660255 ↗

“This is a preliminary study designed to assess the safety and properties of a new oral formulation containing the two most common cannabinoids used for medicinal purposes -...” NCT03936907 ↗

“This Phase I randomized controlled trial aimed to assess the safety and tolerability of cannabidiol (CBD) and alcohol co-administration among moderate alcohol consumers in...” PMID 42288934 ↗ Jun 2026

“Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its anti-inflammatory, analgesic,...” NCT07552974 ↗

“The primary goal of this pilot project is to demonstrate the safety and feasibility of using Cannabidiol (CBD) in combination with standard of care prolonged exposure (PE)...” NCT05132699 ↗

“Full-spectrum Cannabis sativa extract containing cannabidiol (CBD) 100 mg/mL and tetrahydrocannabinol (THC) 3.33 mg/mL, administered sublingually for 12 weeks according to a...” NCT07696871 ↗

“This study will explore the effectiveness and tolerability of Cannabidiol (CBD) in the treatment of alcohol withdrawal symptoms in an inpatient setting, in a double-blind...” NCT04205682 ↗

“oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener...” NCT04421456 ↗

“Cannabidiol (CBD), the non-intoxicating component of cannabis, has known neuroprotective, antiepileptic, anxiolytic, and antipsychotic effects and may be useful in treating the...” PMID 41103807 ↗ Jan 2025

“Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in...” NCT01606137 ↗

“More recently, there's been considerable excitement in the press over the potential therapeutic use of cannabidiol (CBD) products in the treatment of a variety of physical and...” NCT04197102 ↗

“This is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications after a...” NCT05934500 ↗

“The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced...” NCT04398446 ↗

“This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered...” NCT03467113 ↗

“To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic...” NCT04989413 ↗

“Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg...” NCT03005119 ↗

“It consists of a cannabidiol (CBD) solution for oral administration: EPIDYOLEX® will be administered orally in two equal doses per day, 12 hours apart, preferably with...” NCT07564245 ↗

“Cannabidiol, or CBD, is an over-the-counter "nutraceutical" that is more commonly being used by healthy adults for pain management, recovery from strenuous exercise, and...” NCT05456113 ↗

“Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as an OTC supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies.” NCT04603391 ↗

“The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule).” NCT03787628 ↗

“Oral cannabidiol (CBD; 7.2 mg/kg/day), tetrahydrocannabinol (THC; 0.257 mg/kg/day, equivalent to 1:28 of the CBD dose), and terpenes (0.5 mg/kg/day), administered in two daily doses.” NCT07199218 ↗

“Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water” NCT03627117 ↗

“A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults” NCT02224690 ↗

“This study will obtain preliminary information about whether, and at what dose, cannabidiol (CBD) may help with insomnia in people living with human immunodeficiency virus (HIV).” NCT05097651 ↗

“One promising new compound for the treatment of alcohol craving in AD is Cannabidiol (CBD), which showed beneficial effects on alcohol craving in preliminary clinical studies.” NCT06845124 ↗

“This study is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications.” NCT05240755 ↗

“Cannabidiol (CBD) has been approved as a treatment for rare childhood epilepsies and could be an effective treatment for psychotic disorders, anxiety disorders and addictions.” NCT05032807 ↗

“We conducted a double-blind, placebo-controlled crossover study of plant-derived CBD (Epidiolex®) to determine safety, tolerability, and behavior effects in autistic boys.” PMID 40410546 ↗ May 2025

“The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Ankle and Tibia Fracture Open Reduction and Internal Fixation. A Double-Blind, Randomized Control Study” NCT04768478 ↗

“This trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.” NCT04105231 ↗

“Drug: Cannabidiol An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day. Other Names: CBD” NCT04044729 ↗

“The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain.” NCT05076370 ↗

“Cannabidiol (CBD) is the active ingredient of interest because of its anti-inflammatory effects and lack of psychoactive effects seen with tetrahydrocannabinol (THC).” NCT03825965 ↗

“Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumour effect with temozolomide and radiotherapy in preclinical glioma models.” NCT03529448 ↗

“The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects.” NCT04816994 ↗

“The co-administration of tetrahydrocannabinol (THC) with cannabidiol (CBD) may translate into additional therapeutic benefits with an attenuation of adverse effects.” NCT02283281 ↗

“Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).” NCT02249299 ↗

“BACKGROUND: Cannabidiol (CBD) has been shown recently to positively affect patient pain and satisfaction immediately after arthroscopic rotator cuff repair (ARCR).” PMID 38322981 ↗ Feb 2024

“Do cannabidiol (CBD) or vagus nerve stimulation reduce the frequency of persistent post-traumatic headache more than traditional oral headache medications?” NCT07624279 ↗

“Cannabidiol (CBD), a constituent of the Cannabis sativa plant, may be a promising candidate pharmacotherapy due to its potential therapeutic properties” PMID 40500407 ↗ Jun 2025

“Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties.” NCT05457465 ↗

“Prior work indicates that cannabidiol (CBD) might reduce inflammation; however, the genetics underpinning of this effect are not well investigated.” PMID 38252549 ↗ Jan 2024

“Cannabidiol (CBD) as Liquid Structure Formulation Nantheia ATL5 400mg will be administered twice a day in 100mg softgel capsules to CBD Group.” NCT05269459 ↗

“In particular the cannabinoid compound cannabidiol (CBD) displays a highly favourable profile for development as a new antipsychotic agent.” NCT02932605 ↗

“Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties.” PMID 26033282 ↗ May 2015

“Cannabidiol (CBD) has anxiolytic and antidepressant properties and may be capable of reducing emotional exhaustion and burnout symptoms.” PMID 34387679 ↗ Aug 2021

“Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties.” NCT04731116 ↗

“Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties.” NCT02392780 ↗

“Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties.” NCT02478424 ↗

“The active study intervention, T2:C100, is an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a digestible oil.” NCT05644262 ↗

“The suppression of chronic periodontitis after application of dental gel and toothpaste containing cannabidiol (CBD) will be evaluated.” NCT05498012 ↗

“The Safety and Efficacy of Treatment With Cannabidiol (CBD) Oil Enriched With Terpenes, Devoid of THC, in Children Diagnosed With ADHD” NCT06542445 ↗

“An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.” NCT03215940 ↗

“This study investigates the effect of 246 milligrams (mg) of Cannabidiol (CBD) on the learning and memory scores of human subjects” NCT06074172 ↗

“Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die” NCT04607603 ↗

“oral tablet formulation of natural Cannabidiol (CBD) at 40 mg and 100 mg alone and in combination with Tetrahydrocannabinol (THC)” NCT04226690 ↗

“Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.” NCT01610713 ↗

“peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days” PMID 41252210 ↗ Nov 2025

“Cannabidiol (CBD), a cannabinoid receptor 2 inverse agonist with central effects, also reduces gut sensation and inflammation.” PMID 37482172 ↗ Jul 2023

“Preliminary data suggest that cannabidiol (CBD) may be a potential adjunctive treatment to MOUD by attenuating cue-reactivity.” PMID 37065899 ↗ Mar 2023

“CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)” NCT05283161 ↗

“delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent cannabinoids in most varieties of cannabis.” NCT06192589 ↗

“The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice.” NCT05159830 ↗

“Cannabidiol (CBD) has anti-nociceptive and anti-inflammatory properties, making it a potential treatment option for AIMSS.” PMID 40751295 ↗ Aug 2025

“cannabidiol (CBD), a nonpsychoactive component of cannabis, specifically inhibited cue- induced heroin-seeking behavior.” NCT01311778 ↗

“ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule).” NCT06218056 ↗

“A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.” NCT04088929 ↗

“The two main phytocannabinoids-delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)-have been extensively studied” PMID 33304282 ↗ Nov 2020

“The study intervention involves the administration of high purity Cannabidiol (CBD) in vegan soft gel capsule form.” NCT06514066 ↗

“There are no definitive studies on the efficacy of topical Cannabidiol (CBD) for treating pruritus in SSc patients.” NCT07245238 ↗

“This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.” NCT07434895 ↗

“Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits.” NCT04527003 ↗

“BACKGROUND: Cannabidiol (CBD) is an anti-inflammatory cannabinoid shown to be beneficial in a mouse model of IBD.” PMID 28349233 ↗ Mar 2017

“Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) - inhaled and vaporised cannabis flower” NCT04851392 ↗

“Among these compounds, tetrahydrocannabinol (THC) and cannabidiol (CBD), have received significant attention.” NCT06672666 ↗

“Cannabidiol (CBD) Cannabis Extract Oral Solution for Drug Resistant Pediatric Epilepsy (Expanded Access Use)” NCT03676049 ↗

“OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy.” PMID 40846590 ↗ Aug 2025

“low dose cannabidiol (CBD; Epidiolex) as adjunctive therapy for idiopathic adult-onset blepharospasm (BPS)” PMID 37606606 ↗ Aug 2023

“cannabidiol (CBD) may influence endocannabinoid function without directly acting on cannabinoid receptors.” PMID 36493386 ↗ Dec 2022

“Cannabidiol (CBD) investigated safety, tolerability, pharmacokinetics, and symptomatic improvement in AN.” PMID 41906184 ↗ Mar 2026

“hemp-derived cannabidiol (CBD) and terpenes produced as a potential sleep aid for people with insomnia.” NCT05233761 ↗

“Safety and Efficacy of CBD (Epidiolex) in Idiopathic Generalized Epilepsy With Typical Absence Seizures” NCT04899050 ↗

“co-administration of two constituents of cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” PMID 40611810 ↗ Jul 2025

“Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.” NCT05387148 ↗

“Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function” NCT02291562 ↗

“Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy” NCT04056442 ↗

“The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.” NCT02818777 ↗

“Evidence indicates cannabidiol (CBD) might be beneficial for treating cannabis use disorder.” PMID 36598543 ↗ Jan 2023

“Women were randomized 1:1 to cannabidiol (CBD) vs. delta-9-tetrahydrocannabinol (THC) balms.” PMID 41467893 ↗ Dec 2025

“MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation” NCT05351905 ↗

“Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma” NCT04821856 ↗

“Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa” NCT06108349 ↗

“S1-221 is a liquid containing cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC).” NCT07146945 ↗

“These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).” NCT00397605 ↗

“Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).” NCT06615284 ↗

“A Phase 1a "Window Trial" of Cannabidiol (CBD) For Breast Cancer Primary Tumors” NCT06148038 ↗

“Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).” NCT03805750 ↗

“Cannabidiol (CBD) has emerged as a potential treatment for chronic pain” PMID 38951902 ↗ Jun 2024

“Participants in this arm will receive Cannabidiol (CBD) for 12 weeks.” NCT07326124 ↗

“Prospective Evaluation of Cannabidiol (CBD) on Anxiety: A Pilot Study” NCT04267679 ↗

“In this study, Cannabidiol Oral Solution (CBD) product will be used.” NCT04411225 ↗

“Each mL of MediCabilis provides: * 50 mg of Cannabidiol (CBD+CBDA)” NCT04997954 ↗

“cannabidiol (CBD), a major non-intoxicating constituent of cannabis” NCT02548559 ↗

“Cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain” NCT05020028 ↗

“Cannabidiol (CBD), a chemical from the Cannabis sativa plant” NCT05867849 ↗

“cannabidiol (CBD), a cannabinoid compound found in marijuana” NCT02902081 ↗

“Cannabidiol (CBD), a principal phytocannabinoid constituent” PMID 33995015 ↗ Apr 2021

“Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil” NCT06362889 ↗

“delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” NCT07471347 ↗

“delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” NCT01502046 ↗

“Cannabidiol (CBD) twice daily taken orally for 4-weeks” NCT06930703 ↗

“FDA-approved cannabinoid cannabidiol (CBD; Epidiolex)” NCT04036968 ↗

“adding cannabidiol (CBD) to the existing treatment” NCT06778564 ↗

“Group 1 cannabidiol (CBD) with silicone ointment” NCT05650697 ↗

“RLS103 (cannabidiol \[CBD\] inhaled dry powder)” NCT05429788 ↗

“Cannabidiol (CBD) capsule containing 75mg CBD” NCT05840822 ↗

“RLS103 (Inhaled Dry Powder Cannabidiol [CBD])” NCT05678881 ↗

“hemp-based Cannabidiol (CBD) topical products” NCT04741477 ↗

“Formulation: CBD (99%; 0.1% THC isolate)” NCT06204003 ↗

“exposed to Δ9-THC and cannabidiol (CBD)” NCT05306249 ↗

“Cannabidiol (CBD) tablets of 10mg each” NCT03693833 ↗

“Cannabidiol (CBD) Oil, 300mg, 1 dose” NCT06686914 ↗

“multiple doses of Cannabidiol (CBD)” NCT03840512 ↗

“Full-Spectrum Cannabidiol (CBD)” NCT07279558 ↗

“plant-derived cannabidiol (CBD)” NCT06575751 ↗

“Cannabidiol (CBD) oral solution” NCT07298408 ↗

“Cannabidiol (CBD) oral solution” NCT07668856 ↗

“Cannabidiol (CBD) Oil Capsules” NCT03549819 ↗

“cannabidiol is abbreviated CBD” NCT01844687 ↗

“Epidiolex (cannabidiol) (CBD)” NCT04732169 ↗

“Cannabidiol (CBD) Topical Gel” NCT07445568 ↗

“300 mg Cannabidiol (CBD) oil” NCT04590495 ↗

“600 mg cannabidiol (CBD)” NCT04883255 ↗

“50 mg Cannabidiol (CBD)” NCT05253417 ↗

“Drug: Cannabidiol (CBD)” NCT05753007 ↗

“Cannabidiol (CBD) 200mg” NCT06206291 ↗

“Cannabidiol (CBD) only” NCT06222268 ↗

“Cannabidiol (CBD) Gel” NCT07027566 ↗

“cannabidiol or CBD” NCT06414473 ↗

“Cannabidiol (CBD)” NCT04760613 ↗

“Cannabidiol (CBD)” NCT05269628 ↗

“Cannabidiol (CBD)” NCT04567784 ↗

“Cannabidiol (CBD)” NCT06695195 ↗

“Cannabidiol (CBD)” NCT04992624 ↗

“Cannabidiol (CBD)” NCT04193631 ↗

“cannabidiol (CBD)” NCT02556008 ↗

“cannabidiol (CBD)” NCT02255292 ↗

“Cannabidiol (CBD)” NCT03883360 ↗

“Cannabidiol (CBD)” NCT07434973 ↗

“Cannabidiol (CBD)” NCT07148843 ↗

“CBD” NCT02559167 ↗

NCT06738732 ↗

NCT03245658 ↗

NCT06014424 ↗

NCT05562635 ↗

NCT06840899 ↗

NCT05037487 ↗

NCT02083874 ↗

NCT04201197 ↗

NCT06129591 ↗

NCT06859710 ↗

NCT05121506 ↗

NCT04283019 ↗

NCT05049733 ↗

NCT04855526 ↗

NCT04059978 ↗

NCT04775030 ↗

NCT04286594 ↗

NCT03550352 ↗

NCT03832816 ↗

NCT05067387 ↗

NCT05066308 ↗

NCT03635593 ↗

NCT04439955 ↗
Known as CBD oil “This is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications after a...” NCT05934500 ↗
1

“determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants” NCT04436081 ↗
Known as CBD-OS “The aim of the study is to evaluate the effect of cannabidiol (CBD-OS®) on cognitive functions in patients aged from 2 to 18 years old diagnosed with Dravet syndrome or...” NCT04611438 ↗
1

NCT07233239 ↗
Known as CBDE “after a single dose of CBDE (cannabidiol extract), although the plan is to extend these studies to multiple dose administrations in the future” NCT04280289 ↗
Known as DAC C-052 “DAC C-052 "Cannabidiol" / NRF 22.10 "Oily cannabidiol solution 100 mg/ml"” NCT04790136 ↗
Known as Defined CBD “Defined CBD is a capsule composed of highly purified (\>99.9%) hemp-derived cannabidiol (CBD) and terpenes produced as a potential sleep aid for people with insomnia.” NCT05233761 ↗
Known as Epidiolex “We performed a randomized, double-blinded, placebo-controlled study of CBD twice daily (Epidiolex escalated to 20 mg/kg/d; Jazz Pharmaceuticals, Dublin, Ireland) in patients...” PMID 37482172 ↗ Jul 2023
24

“Epidyolex, marketed and sold in the US and Canada as Epidiolex, is currently the only marketed CBD monotherapy with US FDA and Health Canada approval and is approved for...” NCT06578455 ↗

“Patients who completed the randomized trial enrolled to receive CBD (Epidiolex® in the United States; Epidyolex® in the EU; 100 mg/mL oral solution).” PMID 34957550 ↗ Dec 2021

“peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days” PMID 41252210 ↗ Nov 2025

“Study intervention is 98% pure CBD. The CBD is Greenwich Biosciences, Inc.'s 100mg/mL oral solution, brand name EPIDIOLEX.” NCT03900923 ↗

“Epidiolex (Cannabidiol) is a colorless to yellow solution in a 100mL vial that is to be administered with a 5mL syringe.” NCT04721691 ↗

“Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution” NCT05044819 ↗

“Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.” NCT04777643 ↗

“low dose cannabidiol (CBD; Epidiolex) as adjunctive therapy for idiopathic adult-onset blepharospasm (BPS)” PMID 37606606 ↗ Aug 2023

“Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL.” NCT04982029 ↗

“FDA-approved cannabinoid cannabidiol (CBD; Epidiolex)” NCT04036968 ↗

“300mg Cannabidiol (3mL Epidiolex), oral, single-dose” NCT05649059 ↗

“Epidiolex (cannabidiol) (CBD)” NCT04732169 ↗

“Cannabidiol (Epidiolex)” NCT02397863 ↗

“Epidiolex” NCT02607891 ↗

NCT04238754 ↗

NCT04231643 ↗

NCT06381791 ↗

NCT04517799 ↗

NCT02695537 ↗

NCT06333041 ↗

NCT04642404 ↗

NCT04428203 ↗

NCT02700412 ↗

NCT07148206 ↗
Known as Epidyolex “Patients received plant-derived, highly purified cannabidiol medicine (Epidiolex® in the USA; Epidyolex® in the EU; 100 mg/mL oral solution) at a dose of 20 mg/kg/day from day...” PMID 32350749 ↗ Jun 2020
3

“Patients who completed the randomized trial enrolled to receive CBD (Epidiolex® in the United States; Epidyolex® in the EU; 100 mg/mL oral solution).” PMID 34957550 ↗ Dec 2021

“a plant-derived, highly purified pharmaceutical formulation of cannabidiol (Epidiolex® [US]/Epidyolex® [EU], 100 mg/mL oral solution)” PMID 42435131 ↗ Jul 2026

“Cannabidiol Epidyolex 100 mg/ml” NCT07462559 ↗
Known as fsCBD “Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used” NCT06290063 ↗